Table 2: Correlation analysis between the biomarkers. Data are presented for all
tumors and stratified by p16 status. Numbers in bold represent significant
correlations.
|
|
p16 |
CD44 |
C-MET |
EGFR |
MTOR |
|
CD44 all p16+ p16- |
0.28 (p=0.004) |
|
|
|
|
|
C-MET all p16+ p16- |
-0.08 (p=0.37) |
0.05 (p=0.61) 0.10 (p=0.49) 0.00 (p=0.997) |
|
|
|
|
EGFR all p16+ p16- |
-0.17 (p=0.08) |
0.02 (p=0.85) -0.20 (p=0.15) 0.11 (p=0.43) |
-0.03 (p=0.79) -0.02 (p=0.88) -0.044 (p=0.75) |
|
|
|
MTOR all p16+ p16- |
-0.12 (p=0.22) |
0.37 (p<0.001) 0.32 (p=0.02) 0.39 (p=0.004) |
0.24 (p=0.01) 0.16 (p=0.28) 0.03 (p=0.03) |
-0.11 (p=0.23) -0.24 (p=0.08) -0.05 (p=0.74) |
|
|
GLUT1 all p16+ p16- |
-0.12 (p=0.23) |
0.33 (p=0.001) 0.17 (p=0.21) 0.41 (p=0.005) |
0.05 (p=0.62) 0.08 (p=0.55) 0.01 (p=0.95) |
0.09 (p=0.36) -0.04 (p=0.77) 0.16 (p=0.28) |
0.30 (p=0.002) 0.30 (p=0.03) 0.28 (p=0.0.063) |